logo-loader
viewSynairgen PLC

Synairgen plc looking for more collaborations, says chief

Respiratory drug group Synairgen plc (LON:SNG) took a step forward in developing a treatment for a fatal lung disease this month when it announced  positive results from its on-going collaboration with Pharmaxis.

Chief executive Richard Marsden tells Proactive “fibrosis is a really hot area and lots of the big pharma companies want drugs which are anti-fibrotic”.

He adds that the next thing for the company is to start clinical trials in 2017, but also notes that Synairgen will work on additional partnership deals.

Quick facts: Synairgen PLC

Price: 35 GBX

AIM:SNG
Market: AIM
Market Cap: £52.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read